| Nitazoxanide/azithromycin combination for COVID-19: A suggested new protocol for early management MT Kelleni Pharmacological research 157, 104874, 2020 | 138 | 2020 |
| Nonalcoholic fatty liver disease: current and potential therapies MA Ibrahim, M Kelleni, A Geddawy Life sciences 92 (2), 114-118, 2013 | 116 | 2013 |
| Early use of non-steroidal anti-inflammatory drugs in COVID-19 might reverse pathogenesis, prevent complications and improve clinical outcomes MT Kelleni Biomedicine & Pharmacotherapy 133, 110982, 2021 | 93 | 2021 |
| Effect of metformin and sitagliptin on doxorubicin-induced cardiotoxicity in rats: impact of oxidative stress, inflammation, and apoptosis MT Kelleni, EF Amin, AM Abdelrahman Journal of toxicology 2015, 2015 | 75 | 2015 |
| Tocilizumab, remdesivir, favipiravir, and dexamethasone repurposed for COVID-19: a comprehensive clinical and pharmacovigilant reassessment MT Kelleni SN Comprehensive Clinical Medicine 3 (4), 919-923, 2021 | 48 | 2021 |
| Resveratrol protects against cisplatin-induced ovarian and uterine toxicity in female rats by attenuating oxidative stress, inflammation and apoptosis MA Ibrahim, IA Albahlol, FA Wani, AAE Tammam, MT Kelleni, MU Sayeed, ... Chemico-Biological Interactions 338, 109402, 2021 | 45 | 2021 |
| NSAIDs/nitazoxanide/azithromycin repurposed for COVID-19: potential mitigation of the cytokine storm interleukin-6 amplifier via immunomodulatory effects MT Kelleni Expert Review of Anti-infective Therapy 20 (1), 17-21, 2022 | 40 | 2022 |
| Effect of captopril and telmisartan on methotrexate-induced hepatotoxicity in rats: impact of oxidative stress, inflammation and apoptosis MT Kelleni, SA Ibrahim, AM Abdelrahman Toxicology mechanisms and methods 26 (5), 371-377, 2016 | 39 | 2016 |
| ACEIs, ARBs, ibuprofen originally linked to COVID-19: the other side of the mirror MT Kelleni Inflammopharmacology 28 (6), 1477-1480, 2020 | 33 | 2020 |
| Drug induced cardiotoxicity: mechanism, prevention and management MT Kelleni, M Abdelbasset Cardiotoxicity, 2018 | 32 | 2018 |
| Nitro-aspirin is a potential therapy for non alcoholic fatty liver disease M Ibrahim, E Farghaly, W Gomaa, M Kelleni, AM Abdelrahman European journal of pharmacology 659 (2-3), 289-295, 2011 | 31 | 2011 |
| Resveratrol-zinc nanoparticles or pterostilbene-zinc: Potential COVID-19 mono and adjuvant therapy MT Kelleni Biomedicine & Pharmacotherapy 139, 111626, 2021 | 27 | 2021 |
| COVID-19, Ebola virus disease, and Nipah virus infection reclassification as novel acute immune dysrhythmia syndrome (n-AIDS): potential crucial role for immunomodulators MT Kelleni Immunologic Research, 2021 | 17 | 2021 |
| Evolution of SARS CoV-2 omicron subvariants BF. 7 and XBB. 1.5: time to follow Africa and abort all COVID restrictions MT Kelleni Journal of Infection 86 (4), 405, 2023 | 15 | 2023 |
| NSAIDs and Kelleni’s protocol as potential early COVID-19 treatment game changer: could it be the final countdown? MT Kelleni Inflammopharmacology 30 (1), 343-348, 2022 | 15 | 2022 |
| NSAIDs/Nitazoxanide/Azithromycin Immunomodulatory Protocol Used in Adult, Geriatric, Pediatric, Pregnant, and Immunocompromised COVID-19 Patients: A Real-World Experience MT Kelleni Canadian Journal of Medicine 3, 121-143, 2021 | 13 | 2021 |
| SARS CoV-2 viral load might not be the right predictor of COVID-19 mortality MT Kelleni Journal of Infection 82 (2), e35, 2021 | 13 | 2021 |
| Real-life practice of the Egyptian Kelleni's protocol in the current tripledemic: COVID-19, RSV and influenza MT Kelleni Journal of Infection 86 (2), 154-225, 2023 | 11 | 2023 |
| NSAIDs/nitazoxanide/azithromycin immunomodulatory protocol used in adults, geriatric, pediatric, pregnant, and immunocompromised COVID-19 patients: a prospective observational … M Kelleni | 11 | 2021 |
| SARS-CoV-2 vaccination, autoimmunity, antibody dependent Covid-19 enhancement and other potential risks: Beneath the tip of the iceberg MT Kelleni Int J Pulm Respir Sci 5 (2), 1-10, 2021 | 11 | 2021 |
